Paroxysmal Supraventricular Tachycardia
📧 Sign up to get email alerts when something new happens for Paroxysmal Supraventricular Tachycardia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia [Phase 3]
Milestone Pharmaceuticals is conducting a Phase 3 study of Etripamil nasal spray for paroxysmal supraventricular tachycardia, with enrollmen…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: The Best Workflow for Paroxysmal Supraventricular Tachycardia Ablation With Zero-fluoroscopy [NA]
Clinical trial update on zero-fluoroscopy ablation workflow for paroxysmal supraventricular tachycardia. Enrollment is by invitation at Nati…
-
FDA approval · 2026-01-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for a generic diltiazem hydrochloride product from Slate Run Pharmaceuticals, LLC under an ANDA.
-
FDA approval · 2025-11-14FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves the original application for diltiazem hydrochloride (Alembic Pharmaceuticals Limited), a generic product, for use in treating …
-
FDA approval · 2025-08-08FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for Diltiazem Hydrochloride by Alembic Pharmaceuticals Inc. The action represents a supplemental reg…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-01Clinical Trial Update: The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients) [Phase 2]
Milestone's Phase 2 pediatric study evaluates Etripamil nasal spray for paroxysmal supraventricular tachycardia and is currently recruiting.
-
FDA approval · 2025-07-10FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for diltiazem hydrochloride (generic) from Sun Pharmaceutical Industries, Inc. under an ANDA. This a…
-
CLINICAL_TRIALS trial_result · 2025-07-03Clinical Trial Update: APART: Prevention and Automatic Therapy of Atrial Arrhythmias in Patients With Paroxysmal Supraventricular Tachycardias [NA]
Completed results of the APART trial evaluating prevention and automatic therapy of atrial arrhythmias in patients with paroxysmal supravent…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Safety and Efficacy Study of the First Domestically Produced FireMagic™ PreciSense™ 3D Microelectrode Ablation Catheter Therapy for Rapid Arrhythmia With Tissue Temperature Measurement Function [NA]
A clinical trial is evaluating the safety and efficacy of a domestically produced FireMagic PreciSense 3D microelectrode ablation catheter f…
-
CLINICAL_TRIALS trial_result · 2025-05-28Clinical Trial Update: A Multicenter Study of Pulsed Field Ablation for Paroxysmal Supraventricular Tachycardia [NA]
Clinical trial completion update for a multicenter study evaluating pulsed field ablation to treat paroxysmal supraventricular tachycardia (…
-
FDA approval · 2025-04-16FDA Approved: CARDIZEM LA — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for Cardizem LA (diltiazem hydrochloride extended-release) submitted by Bausch Health US LLC.
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: prehospItal maNagement oF paroxysmaL supraventrICular Tachycardia
The completed study assessed prehospital management of paroxysmal supraventricular tachycardia conducted in Bologna, Italy.
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia [Phase 3]
Phase 3 trial evaluating etripamil nasal spray for self-administered termination of spontaneous episodes of paroxysmal supraventricular tach…
-
CLINICAL_TRIALS research · 2024-12-13Clinical Trial Update: Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients [Phase 3]
A Phase 3 trial is evaluating the efficacy of adenosine compared with verapamil for paroxysmal supraventricular tachycardia and is currently…
-
CLINICAL_TRIALS research · 2024-10-24Clinical Trial Update: Outcomes of PFA Vs. RFA for Patients with PSVT: a Retrospective and Propensity Score Matching Study
A retrospective study comparing pulsed-field ablation (PFA) versus radiofrequency ablation (RFA) for paroxysmal supraventricular tachycardia…
-
FDA approval · 2024-09-12FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for diltiazem hydrochloride by Mylan Pharmaceuticals Inc. under ANDA074910, indicating regulatory ap…
-
CLINICAL_TRIALS research · 2024-08-21Clinical Trial Update: MCG for Localization of Tachyarrhythmia's Origin [NA]
A clinical trial update from Qilu Hospital of Shandong University describes using magnetocardiography to localize the origin of tachyarrhyth…
-
FDA label_change · 2024-08-13FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for MATZIM LA (diltiazem hydrochloride) from Actavis Pharma, Inc. to update labeling for this long-a…
-
FDA approval · 2024-07-16FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for MATZIM LA (diltiazem hydrochloride) from Actavis Pharma, Inc.
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). [Phase 3]
Milestone Pharmaceuticals announced termination of a Phase 3 trial evaluating etripamil for termination of spontaneous paroxysmal supraventr…
-
FDA approval · 2024-07-03FDA Approved: ADENOSINE — Supplemental Application (Mylan Institutional LLC)
FDA has approved a supplemental application for adenosine (generic) from Mylan Institutional LLC, expanding access to the injectable drug.
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia. NODE-303 [Phase 3]
Phase 3 safety study of etripamil nasal spray for paroxysmal supraventricular tachycardia has completed, with results posted.
-
FDA approval · 2024-04-23FDA Approved: VERAPAMIL HYDROCHLORIDE — Original Application (FRESENIUS KABI USA, LLC)
FDA approved the original application for Verapamil hydrochloride as a generic drug, manufactured by Fresenius Kabi USA, LLC. Verapamil hydr…
-
CLINICAL_TRIALS trial_result · 2023-04-24Clinical Trial Update: Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302 [Phase 3]
Milestone's Phase 3 safety trial of intranasal ettripamil for terminating paroxysmal supraventricular tachycardia was terminated, with resul…
-
FDA approval · 2022-09-23FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (ScieGen Pharmaceuticals, Inc)
FDA approves ScieGen's generic diltiazem hydrochloride under an Original Application (ANDA).